Aldehyde Oxidase

An aldehyde oxidoreductase expressed predominantly in the LIVER; LUNGS; and KIDNEY. It catalyzes the oxidation of a variety of organic aldehydes and N-heterocyclic compounds to CARBOXYLIC ACIDS, and also oxidizes quinoline and pyridine derivatives. The enzyme utilizes molybdenum cofactor and FAD as cofactors.

Also Known As:

Networked: 52 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Goto, Hirohiko: 2 articles (01/2021 - 12/2018)
2.	Ishii, Yuji: 2 articles (01/2021 - 12/2018)
3.	Takeuchi, Kenji: 2 articles (01/2021 - 12/2018)
4.	Yokouchi, Chie: 2 articles (01/2021 - 12/2018)
5.	Maiti, Kaushik: 2 articles (02/2020 - 10/2017)
6.	Smith, Roger: 2 articles (02/2020 - 10/2017)
7.	Sultana, Zakia: 2 articles (02/2020 - 10/2017)
8.	Ichida, Kimiyoshi: 2 articles (11/2016 - 11/2012)
9.	Garattini, Enrico: 2 articles (08/2011 - 02/2005)
10.	Terao, Mineko: 2 articles (08/2011 - 02/2005)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2020 - "Only gene AOX1, encoding aldehyde oxidase 1, was ubiquitously downregulated, Furthermore, we observed that the 62 genes were widely and strongly correlated in normal controls, however, the gene pair correlations were significantly lost in tumor patients for all 12 types of cancer. " 08/01/2011 - "We highlight the potential offered by human aldehyde oxidase targeting for the development of new pharmacological agents, limiting our attention to the realms of antiobesity and anti-cancer drugs. " 04/01/1996 - "The results indicate that the superior activity of MDAM relative to MTX may be partially due to a combination of enhanced transport to tumor cells and slower deactivation by aldehyde oxidase." 05/15/1994 - "Aldehyde oxidase activity was found in normal liver tissue but not in other normal or tumor tissues. " 07/01/1987 - "Because TBM is capable of overcoming at least one of the modalities of MTX resistance, defective polyglutamylation, and may be more efficiently detoxified than MTX by the action of hepatic aldehyde oxidase, it has the potential to be a useful agent for the treatment of MTX-resistant tumors."
2.	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 11/01/1995 - "Lou Gehrig's disease linked to aldehyde oxidase." 02/01/2020 - "Inhibition of vertebrate aldehyde oxidase as a therapeutic treatment for cancer, obesity, aging and amyotrophic lateral sclerosis." 07/07/1997 - "Aldehyde oxidase (AO), a protein involved in the catabolism of catecholamines, is the product of a gene potentially responsible for one of the familial forms of the motor neuron disease, amyotrophic lateral sclerosis (ALS). " 03/01/1995 - "Analysis of aldehyde oxidase and xanthine dehydrogenase/oxidase as possible candidate genes for autosomal recessive familial amyotrophic lateral sclerosis."
3.	Fatty Liver 01/01/2021 - "This finding was attributed to the MNA metabolism inhibition by HYD, which is a strong inhibitor of aldehyde oxidase (AO); this results in an increase in hepatic MNA and improved fatty liver. " 12/09/2018 - "We hypothesised that fatty liver improvement by MNA would be further enhanced by suppressing its rapid metabolism by aldehyde oxidase in the liver. " 12/09/2018 - "Alleviation of fatty liver in a rat model by enhancing N1-methylnicotinamide bioavailability through aldehyde oxidase inhibition." 01/01/2021 - "Reduction of fatty liver in rats by nicotinamide via the regeneration of the methionine cycle and the inhibition of aldehyde oxidase."
4.	Obesity 02/01/2020 - "Inhibition of vertebrate aldehyde oxidase as a therapeutic treatment for cancer, obesity, aging and amyotrophic lateral sclerosis."
5.	Hypoxia (Hypoxemia) 11/01/1990 - "These results indicate that the oxidative pathway catalyzed by cytochrome P-450-dependent monooxygenase is predominant in DPSO metabolism under normoxic conditions, whereas only under hypoxia does the reductive pathway become the major one if an electron donor for aldehyde oxidase exists in intact guinea pig liver." 11/01/1990 - "On the other hand, coinfusion of an electron donor for aldehyde oxidase such as 2-hydroxypyrimidine and benzaldehyde, but not xanthine, markedly stimulated the formation of DPS during hypoxia. " 01/01/2017 - "To date, all the four known human molybdenum-containing enzymes, xanthine oxidase, aldehyde oxidase, sulfite oxidase, and mitochondrial amidoxime-reducing component, have been shown to function as nitrite reductases under hypoxia by biochemical, cellular, or animal studies. "

Related Drugs and Biologics

1.	Xanthine Oxidase
2.	Sulfite Oxidase
3.	Enzymes
4.	Molybdenum
5.	Nitrite Reductases (Nitrite Reductase)
6.	amidoxime
7.	Xanthine Dehydrogenase
8.	Cytochrome P-450 Enzyme System (Cytochrome P450)
9.	molybdopterin (molybdenum cofactor)
10.	Proteins (Proteins, Gene)